This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary question is whether interferon beta is more effective than placebo in decreasing the number of SPMS patients who experience disability progression during follow-up. We also aim to evaluate the incidence and seriousness of side effects and adverse events.
The secondary objectives are to examine the effect of interferon beta on relapses during follow-up, on patient activities of daily living and quality of life, and reducing the need for other treatments. We will also evaluate change in MRI parameters during follow-up.